Sign In
Buy PBYI
$8.04
+0.380 (+4.96%)
At Close: Jun 23, 2026
Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
09:37pm, Thursday, 26'th Feb 2026
Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates
07:46pm, Thursday, 26'th Feb 2026
Puma Biotech (PBYI) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.43 per share a year ago.
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
04:05pm, Thursday, 26'th Feb 2026
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its 4Q-2025 earnings release on Feb. 26 and followed with a conference call to review results.
Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference
04:15pm, Monday, 23'rd Feb 2026
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO & President Alan Auerbach will provide a corporate overview at the TD Cowen Health Care Conference on March 2 at 2:30 pm ET.
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results
04:07pm, Thursday, 12'th Feb 2026
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its fourth quarter and full year 2025 results, followed be a conference call, after the close on Feb. 26, 2026.
Puma Biotechnology (NASDAQ:PBYI) Shares Pass Above 200-Day Moving Average – What’s Next?
03:55am, Tuesday, 10'th Feb 2026
Puma Biotechnology, Inc. (NASDAQ: PBYI - Get Free Report) shares crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $5.27 and traded as high a
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:05pm, Wednesday, 04'th Feb 2026
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported the grant of inducement awards to two new hires in January 2026, as required under Nasdaq Listing Rule 5635(c)(4).
New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Available in Thailand
05:00am, Thursday, 22'nd Jan 2026
Eligible women with breast cancer in Thailand now have access to a new therapy, NERLYNX (neratinib), for the first time The launch of NERLYNX provides an
Puma Biotechnology (NASDAQ:PBYI) Stock Price Crosses Above 200-Day Moving Average – Here’s What Happened
03:55am, Thursday, 08'th Jan 2026
Shares of Puma Biotechnology, Inc. (NASDAQ: PBYI - Get Free Report) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $4.76 and traded as h
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:15pm, Wednesday, 07'th Jan 2026
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards granted to December 2025 new hires, in accordance with Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)
04:10pm, Monday, 22'nd Dec 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology was added to the Nasdaq Biotechnology Index effective after the close of trading on Dec. 19, 2025.
CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?
12:31pm, Wednesday, 17'th Dec 2025
CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:15pm, Tuesday, 02'nd Dec 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 1, 2025, the Compensation Committee of Puma's Board of Directors approved
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick?
01:01pm, Thursday, 27'th Nov 2025
Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.
Puma Biotechnology: Step By Step In Making A Transition
06:02am, Monday, 10'th Nov 2025
Puma Biotechnology has been in something of a stasis for years, selling one drug with no new approvals while developing alisertib. The cash position remains strong enough to carry them through key rea
